www.worldbulletin.net [1] |
Lilly Delays Diabetes Treatment Submission [2]
Wall Street Journal Eli Lilly and Co. said Monday that it would hold off on submitting its late-stage diabetes treatment [3] to both U.S. and European regulatory agencies for approval until it better understands the treatment's potential side effects. Basal insulin peglispro … Lilly delays submission to market once-daily diabetes drug [1]www.worldbulletin.net Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III [4]Zacks.com Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III – Analyst Blog [5]Nasdaq CNNMoney [6] –MarketWatch [7] all 53 news articles » [8] |
More details can be found at www.diabeteshowto.com [9]